The Effects of Different Treatment Modalities on the Disease Course and Survival in Patients with Hepatocellular Cancer


Lacin S. , Karakas Y., DİZDAR Ö. , KILIÇKAP S. , Hassan M. M. , Xiao L., ...More

UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI, vol.30, no.2, pp.94-102, 2020 (Journal Indexed in SCI) identifier identifier

  • Publication Type: Article / Article
  • Volume: 30 Issue: 2
  • Publication Date: 2020
  • Doi Number: 10.4999/uhod.204219
  • Title of Journal : UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI
  • Page Numbers: pp.94-102

Abstract

The overall survival rate of patients with hepatocellular carcinoma (HCC) is still poor, and development of innovative therapy modalities is of crucial importance. We aimed to evaluate the efficacy of available treatment modalities and investigate their impact on survival. Patients with HCC were included to the study. Disease stages were determined according to the most commonly used classification systems. Treatment modalities for patients were determined as local ablative, local palliative, surgery, systemic cytotoxic treatment, tyrosine kinase inhibitors, and best supportive care (BSC).Among 100 patients, 81 were men and 19 were women, the median age was 64. According to the Barcelona Clinic Liver Cancer staging system (BCLC), 1% of the patients were at very early stage, 16.3% early-stage, 22.4% intermediate-stage, 56.1% advanced-stage, and 4.1% was at the terminal-stage. We observed significant difference with regards to overall survival (OS) rates among different disease stage (p< 0.001). Portal vein tumor thrombosis (PVTT) was reported in 42 patients, and the OS rate of patients with PVTT was poor (p= 0.001). Among the first-line treatments, 9 patients received local ablative therapy, 25 local palliative, 27 systemic cytotoxic, 12 tyrosine kinase inhibitors, 10 surgical resection, and 4 BSC. The difference with regards to OS ratios of treatment groups was significant (p< 0.0001). We observed differential impact of diverse treatment modalities on survival of HCC patients. The study also revealed importance of various factors such as tumor size, disease stage, serum alpha-fetoprotein level, hepatic function status, and tumor vascular invasion status on clinical outcome.